Equities Research Analysts’ Downgrades for May, 15th (ETFC, EYE, HOLX, IART, JAKK, LH, LM, O, RE, SUNW)

Share on StockTwits

Equities Research Analysts’ downgrades for Wednesday, May 15th:

E*TRADE Financial (NASDAQ:ETFC) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Shares of E*TRADE have outperformed the industry over the past three months. Also, the company has an impressive earnings surprise history. It surpassed the Zacks Consensus Estimate for earnings in each of the trailing four quarters. First-quarter results benefited from higher revenues, decline in expenses and benefit to provision for loan losses. The company’s several restructuring measures and balance-sheet growth plans keep us encouraged. Also, E*TRADE’s focus on core operations and strategic initiatives along with rising interest rates will likely lead to an improved top-line performance. Further, the company continues to enhance shareholders’ value through capital deployment activities. However, rising costs due to the company's investments in franchise, remain a major concern. Further, intense competition can have an adverse impact on its customer base and consequently on profitability.”

National Vision (NASDAQ:EYE) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “National Vision exceeded the first quarter on a strong note with better-than-expected earnings and revenues. The company has been witnessing positive comps on increased customer transaction for past 69 quarters. However, we are disappointed with the company expecting to report softer comps in the second quarter as compared to the previous projections. According to National Vision, the timing of tax refunds and the size will impede growth. On a positive note, National Vision’s plans to continue to focus on core growth drivers in 2019 buoy optimism. In this regard, the company aims at increasing its store count following a formula-based approach. However, the company’s high dependence on limited number of vendors is a concern. Also, a tough competitive landscape is a threat. Moreover, rising costs can exert pressure on the bottom line. Overall, National Vision has been underperforming its industry in the past three months.”

Hologic (NASDAQ:HOLX) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Hologic exited the second quarter of fiscal 2019 on a solid note. The strong top-line growth was led by solid year-over-year rise in core businesses like Breast Health and Molecular Diagnostics. We are also upbeat about the recent launches like Aptima Mycoplasma genitalium assay and the Unifi Analytics business intelligence tool for mammography centers in the United States, Omnhysteroscope in Europe and Canada, and LOCalize wireless breast lesion localization system in Europe. Hologic has outperformed its industry over the past three months. On the flip side, Hologic's Faxitron and Focal integration related costs are mounting. These have continued to exert pressure on the company's operating margin. This apart volume environment for testing laboratories and utilization weaknesses are looming headwinds. Also, the company operating in a highly competitive landscape is a concern.”

Integra Lifesciences (NASDAQ:IART) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Integra LifeSciences exited the first quarter of 2019 on a mixed note with better-than-expected earnings and a revenue miss. However, organic revenue growth was encouraging and was in line with the company’s expectation. Within global neurosurgery business, sales in dural access and repair increased in mid-single digits on an organic basis with growth in both graft and sealant product lines. Benefiting from product launches and an enhanced sales force performance, the company envisions faster organic growth during the second half of 2019. On the flip side, escalating costs and expenses have been a major headwind for Integra Lifesciences. A tough competitive landscape adds to the woes.”

JAKKS Pacific (NASDAQ:JAKK) was downgraded by analysts at Zacks Investment Research from a buy rating to a sell rating. According to Zacks, “Shares of JAKKS Pacific have underperformed the industry in the past year. The trend is likely to continue in the near term on lower-than-expected results in the first quarter of 2019. A challenging industry scenario for traditional toymakers and the Toys ‘R’ Us liquidation have been affecting JAKKS Pacific’s results for quite some time. Moreover, the company faces challenges in forms of rising costs, competition from alternative modes of entertainment and age compression. However, it is banking on various partnerships and product launches to drive long-term growth. To achieve its long-term growth, JAKKS Pacific is likely to consistently bank on a solid base of evergreen properties, categories, partner brands and licenses by using promotional opportunities. Also, acquisitions, solid international footprint, focus on innovation, and collaborations with popular brands and movie franchisees should boost its top line.”

Laboratory Corp. of America (NYSE:LH) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “LabCorp has outperformed its industry over the three months. In the first quarter of 2019, LabCorp reported strong underlying performance and organic growth across both Diagnostics and Drug Development businesses banking on solid execution of three fundamental strategies. Diagnostics business grew organically in terms of both revenue and volume despite additional price reductions due to PAMA and the loss of exclusivity in two of the company’s largest managed care contracts. This apart, Covance Drug Development has also reported sturdy organic growth. The LaunchPad initiatives are also well on track. New acquisitions like MI Bioresearch and Envigo look promising. On the flip side, the disposition of certain businesses and the implementation of the Protecting Access to Medicare Act (PAMA) dented growth. Unfavorable currency transaction continues to remain as a major headwind. The company expects 2019 to continue to witness similar hurdles.”

Legg Mason (NYSE:LM) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Shares of Legg Mason have outperformed the industry over the past six months. Also, the company has an impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in three of the trailing four quarters. Fourth-quarter fiscal 2019 results benefited from higher assets under management and lower expenses. Legg Mason’s strategic acquisitions over the past few years are anticipated to boost top-line growth. Further, the company's focus on expanding product offerings for its customers bode well for the long term. Sound liquidity position also keeps Legg Mason well poised for growth. However, continued equity AUM outflows and rising costs are key concerns. Also, unsustainable capital deployment activities keep us apprehensive.”

Realty Income (NYSE:O) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Shares of Realty Income have underperformed its industry, over the past three months. However, the recent trend in estimate revisions for 2019 funds from operations (FFO) per share indicates a favorable outlook for the company. Recently, the company announced its first international real estate investment. It derives majority of its annualized retail rental revenues from tenants belonging to service, non-discretionary and low-price retail business. Such businesses are less susceptible to economic recessions, as well as competition from Internet retailing. Furthermore, accretive acquisitions and solid balance-sheet strength augur well for long-term growth. However, the prevalent retail apocalypse is a concern. Moreover, the company’s substantial exposure to single tenant assets raises its risks associated with tenant default.”

Everest Re Group (NYSE:RE) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Everest Re Group’s first-quarter 2019 earnings per share of $6.91 beat the Zacks Consensus Estimate by 9.7% and was up 29.4% year over year. Both its reinsurance and insurance businesses witnessed growth in the quarter. Its global presence, product diversification, capital adequacy, financial flexibility and traditional risk management capabilities are expected to drive growth. The company’s divestment of its underperforming businesses and strengthening reserves are impressive. It enjoys a disciplined capital management strategy. However, its exposure to cat events induces underwriting volatility. Also, a competitive reinsurance market remains a headwind. The company has seen its estimates for 2019 move north by 1.6% in the past seven days. Shares of Everest Re have outperformed the industry in a year’s time.”

Sunworks (NASDAQ:SUNW) was downgraded by analysts at Zacks Investment Research from a strong-buy rating to a hold rating. According to Zacks, “Sunworks, Inc. provides solar power solutions. The company focused on the design, installation and management of solar power systems for commercial, agricultural and residential customers. Sunworks, Inc., formerly known as Solar3D, Inc., is based in Roseville, United States. “

SVMK (NASDAQ:SVMK) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “SVMK Inc. develops survey software. The Company offers a platform which enables organizations to collect and analyze feedback and insights which solves business problems, enhances customer experience and loyalty, improves employee productivity, retention, optimization and marketing investments. SVMK Inc. is based in San Mateo, United States. “

Switch (NYSE:SWCH) was downgraded by analysts at Zacks Investment Research from a strong-buy rating to a hold rating. According to Zacks, “Switch, Inc. is a technology infrastructure company. It designs, constructs and operates hyperscale data centers. The Company is developer and operator of the SUPERNAP, data center facilities, and provides colocation, telecommunications, cloud services and content ecosystems. Switch, Inc. is based in LAS VEGAS, United States. “

SWIRE PAC LTD/S (OTCMKTS:SWRAY) was downgraded by analysts at Zacks Investment Research from a strong-buy rating to a hold rating. According to Zacks, “SWIRE PACIFIC LIMITED is one of Hong Kong’s leading listed companies, with diversified interests in five operating divisions: Property, Aviation, Beverages, Marine Services and Trading & Industrial. The company’s operations are predominantly based in the Greater China region, where the Swire group has been established for over 130 years. Swire Pacific seeks to foster long-term, sustainable growth through active participation in management, underpinned by a strong financial base. “

Receive News & Ratings for E*TRADE Financial Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for E*TRADE Financial Corp and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Shoe Zone  Price Target Increased to GBX 240 by Analysts at FinnCap
Shoe Zone Price Target Increased to GBX 240 by Analysts at FinnCap
Zacks Investment Research Upgrades Great Portland Estates  to Hold
Zacks Investment Research Upgrades Great Portland Estates to Hold
CIP Merchant Capital Ltd  Insider Marco Fumagalli Buys 615,763 Shares
CIP Merchant Capital Ltd Insider Marco Fumagalli Buys 615,763 Shares
Canadian Imperial Bank of Commerce  Price Target Lowered to C$115.00 at National Bank Financial
Canadian Imperial Bank of Commerce Price Target Lowered to C$115.00 at National Bank Financial
Advanced Drainage Systems  Sees Unusually-High Trading Volume Following Strong Earnings
Advanced Drainage Systems Sees Unusually-High Trading Volume Following Strong Earnings
Cellular Biomedicine Group  versus Osiris Therapeutics  Head-To-Head Contrast
Cellular Biomedicine Group versus Osiris Therapeutics Head-To-Head Contrast


 
© 2006-2019 Zolmax.